Healthcare Providers and Services
Company Overview of 23andMe, Inc.
23andMe, Inc. operates as a personal genetics company that provides ancestry-related genetic reports and uninterpreted raw genetic data. The company helps individuals understand their own genetic information through DNA analysis technologies and Web-based interactive tools. Its Personal Genome Service enables individuals to gain deeper insights into their ancestry and inherited traits. The company was founded in 2006 and is based in Mountain View, California.
1390 Shorebird Way
Mountain View, CA 94043
Founded in 2006
Key Executives for 23andMe, Inc.
Co-Founder, Chief Executive Officer and Director
Chief Science Officer and Head of Therapeutics
Chief Legal and Regulatory Officer
Compensation as of Fiscal Year 2014.
23andMe, Inc. Key Developments
23andMe, Inc. Appoints Robert Gentleman as Vice President of Computational Biology
Apr 2 15
23andMe, Inc. announced the appointment of Robert Gentleman, Ph.D., as vice president of computational biology. Dr. Gentleman joins 23andMe to focus on the exploration of how the human genetic and trait data in the 23andMe database can be used to identify new therapies for disease. Most recently, Dr. Gentleman served as senior director of bioinformatics and computational biology at Genentech. In addition to broadly overseeing computational biology activities at the company, Dr. Gentleman will specifically focus on collaborating with Dr. Richard Scheller, 23andMe chief science officer and head of therapeutics. He will work with Dr. Scheller and others to help the newly formed therapeutics group utilize data analytics and theoretical models to identify trends and ultimately advance the drug research and discovery process.
23andMe Appoints Erynn Gordon as Medical Marketing Director
Mar 19 15
23andMe announced the appointment of Erynn Gordon, MS, CGC as medical marketing director. Gordon is a board certified genetic counselor with more than 14 years of clinical and research experience in genetics. Gordon has also served as president of the American Board of Genetic Counseling (ABGC), chair of the ethics advisory board of the National Society of Genetic Counselors (NSGC) and is currently serving as vice chair of the New Jersey Board of Medical Examiners' Genetic Counseling Advisory Committee. In her role at the company, Gordon will oversee engagement with the medical community, as well as strategic initiatives at the company's related to clinical applications. In this capacity, Gordon joins the newly created commercial marketing group led by Ruby Gadelrab, vice president of commercial marketing. Gordon will also work closely with company's chief medical officer, Jill Hagenkord, MD and her medical affairs team. Both Gadelrab and Hagenkord are leading company's efforts to engage the medical and scientific communities. Before joining the company, Gordon was a lead genetic counselor and medical liaison on the commercial team at Invitae.
23andMe Appoints Richard Scheller as Chief Science Officer and Head of Therapeutics
Mar 12 15
23andMe announced the creation of a new therapeutics group and appointment of Richard Scheller, Ph.D. as chief science officer and head of therapeutics to lead it. Dr. Scheller retired in December 2014 from a distinguished 14 year career as an executive at Genentech where he was the executive vice president of research and early development. When Dr. Scheller assumes his post at the beginning of April 2015 as 23andMe's chief science officer and head of therapeutics, he will help build a dedicated research and development team. Dr. Scheller is a member of the American Academy of Arts & Sciences and the National Academy of Sciences. He also currently serves on the Board of Trustees for the California Institute of Technology.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 22, 2014
Most Searched Private Companies
Sponsored Financial Commentaries